Skip to main content
Premium Trial:

Request an Annual Quote

Cellomics Sells ArrayScan System to Vertex

NEW YORK, July 27- Cellomics, a Pittsburgh-based maker of cell-imaging technology, said recently that it sold its ArrayScan HCS System to Vertex Pharmaceuticals of Cambridge, Mass.

The ArrayScan Sytem is an automated system designed to measure and analyze cell activity as a way of determining function. The system can also be used to determine whether a drug is toxic or efficacious, Cellomics said. 

The company did not disclose the amount Vertex paid for the system. To date, Cellomics has placed systems in nine out of ten of the leading pharmaceutical companies. 

In addition to ArrayScan, Cellomics is also developing other screening and bioinformatics products for cell analysis. 

Earlier this month, Cellomics acquired Momentum Healthcare, a developer of drug discovery software.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.